These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32019315)

  • 41. The Epidemiology of Hepatocellular Carcinoma in the USA.
    Kim HS; El-Serag HB
    Curr Gastroenterol Rep; 2019 Apr; 21(4):17. PubMed ID: 30976932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome.
    Friedman SL
    Diabetes Metab J; 2024 Mar; 48(2):161-169. PubMed ID: 38273792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Letter to the Editor: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in Patients With Nonalcoholic Fatty Liver Disease.
    Yang NB; Li GX; Chu JG; Wang YJ
    Hepatology; 2020 Jun; 71(6):2172-2173. PubMed ID: 31849080
    [No Abstract]   [Full Text] [Related]  

  • 44. [Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases].
    Halmos T; Suba I
    Orv Hetil; 2017 Dec; 158(52):2051-2061. PubMed ID: 29285942
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
    Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
    Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
    Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors.
    Juanola O; Martínez-López S; Francés R; Gómez-Hurtado I
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34069012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.
    Ortolan A; Lorenzin M; Tadiotto G; Russo FP; Oliviero F; Felicetti M; D'Incà R; Favero M; Piaserico S; Doria A; Ramonda R
    Clin Rheumatol; 2019 Oct; 38(10):2843-2850. PubMed ID: 31254236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.
    Souza MR; Diniz Mde F; Medeiros-Filho JE; Araújo MS
    Arq Gastroenterol; 2012; 49(1):89-96. PubMed ID: 22481692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin].
    Henrion J; Libon E; De Maeght S; Deltenre P; Schapira M; Ghilain JM; Maisin JM; Heller FR
    Gastroenterol Clin Biol; 2003 May; 27(5):534-9. PubMed ID: 12843918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Kanneganti M; Singal AG
    Gastroenterology; 2022 May; 162(6):1772-1774. PubMed ID: 35120916
    [No Abstract]   [Full Text] [Related]  

  • 54. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review: chronic viral hepatitis and metabolic derangement.
    Wang CC; Cheng PN; Kao JH
    Aliment Pharmacol Ther; 2020 Jan; 51(2):216-230. PubMed ID: 31746482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hepatocellular carcinoma].
    Czauderna C; Marquardt JU; Galle PR; Wörns MA
    Internist (Berl); 2017 May; 58(5):469-479. PubMed ID: 28386626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
    Noureddin M; Rinella ME
    Clin Liver Dis; 2015 May; 19(2):361-79. PubMed ID: 25921668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis.
    Phan J; Ng V; Sheinbaum A; French S; Choi G; El Kabany M; Durazo F; Saab S; Tong M; Busuttil R; Han SH
    J Clin Gastroenterol; 2019 Apr; 53(4):309-313. PubMed ID: 29912756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease.
    El Hadi H; Di Vincenzo A; Vettor R; Rossato M
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The role of metabolic syndrome in gastroenterology].
    Dítě P; Přinosilová J; Dovrtělová L; Kupka T; Nechutová H; Kianička B; Břegová B; Kunovský L; Martínek A; Souček M
    Vnitr Lek; 2015 Sep; 61(9):792-8. PubMed ID: 26465278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.